facebook
Traded Co logo
Submit
Daily limit: 0/10

Contraline Secures $92.5 Million In Series B Funding Led By BVF Partners And RA Capital Management

Property Image

National

See Similar Deals
Leased 06/02/2026
the dealdetailscomps
Property Image

Contraline Secures $92.5 Million In Series B Funding Led By BVF Partners And RA Capital Management

Leased 06/02/2026
the dealdetailscomps

Summary

Contraline has raised $92.5 million in a Series B financing round co-led by BVF Partners L.P. and RA Capital Management. The funds will be utilized to further the late-stage development of NES/T Gel, a reversible hormonal male contraceptive that has recently completed a Phase 2b study and is anticipated to advance to Phase 3 trials in 2027.

Summary of transaction details:

  • Deal Type: Series B
  • Transaction Amount: $92,500,000
  • Company: Contraline
  • Founders: Kevin Eisenfrats & Dr. John Herr
  • Headquarters: Charlottesville, Virginia
  • Notable Investors: BVF Partners L.P., RA Capital Management, GV (Google Ventures), Lumira Ventures, Invus

Contraline is a clinical-stage biopharmaceutical company dedicated to advancing male reproductive health. The co-founder and CEO, Kevin Eisenfrats, highlighted that the financing is crucial for expanding contraceptive options for men and couples. The company is also focused on the development of its non-hormonal ADAM™ program.

Details

IMAGE: a Charlottesville-based clinical-stage biopharmaceutical company focused on male reproductive health, has raised $92.5 million in a Series B round co-led by BVF Partners L.P. and RA Capital Management, with participation from GV (Google Ventures), Lumira Ventures, Invus, and other new and existing investors. The company said proceeds will advance late-stage development of NES/T Gel, a once-daily, reversible hormonal male contraceptive that recently completed a Phase 2b study and is expected to move toward Phase 3 trials in 2027. Co-founder and CEO Kevin Eisenfrats said the financing supports Contraline’s mission to expand contraceptive options for men and couples, as the company also continues development of its non-hormonal ADAM™ program. FOUNDERS: Kevin Eisenfrats & Dr. John Herr INVESTORS: BVF Partners L.P., RA Capital Management, GV (Google Ventures), Lumira Ventures & Invus ROUND: Series B AMOUNT: $92,500,000 HQ: Charlottesville, Virginia

Stay in the Know

Subscribe for insider commercial real estate news, deal highlights, and market insights—delivered straight to your inbox.

By subscribing, you agree to our Terms of Service and Privacy Policy.

Similar Deals

Suggestions
CRE CalculatorAnalyze deals based on income, expenses, and financing. We automatically filled the calculator with data from the deal you are viewing, fill free to modify it to see how it affects the results.
Deal Type
Operating Income
Operating Expenses (Annual)
Net Operating Income (NOI)

$0.00

Debt Service Coverage Ratio (DSCR)

0.00x

Cap Rate

0.00%

Cash Flow (Annual)$0.00
Cash-on-Cash Return0.00%
Monthly Debt Service$0.00
Annual Debt Service$0.00